Sigrid Therapeutics Announces First Patient Treated with SiPore21[®] Medical Device for Sustained Diabetes and Obesity Control
SiPore21® Silica "Molecular Sieves" Offer a Promising Non-Pharmaceutical Alternative
SHINE Trial Marks a Milestone in Prediabetes and Weight Control Research
Stockholm, October 9[th], 2023: Sigrid Therapeutics is pleased to announce the commencement of the SHINE clinical trial for SiPore21® – an innovative medical device designed for sustained diabetes and weight control. Based on Mesoporous Silica particles (MSPs), SiPore21® represents a groundbreaking approach to managing these pressing health concerns. Administered orally in gel form, MSPs act as "molecular sieves," physically